(Q51606241)

8 April 2018

title

Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1518767

4 October 2022

1 reference

A. Rovellini

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1518767

4 October 2022

D. Sommariva

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1518767

4 October 2022

A. Branchi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1518767

4 October 2022

F. Maraffi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1518767

4 October 2022

C. Montalto

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1518767

4 October 2022

R. Gandini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1518767

4 October 2022

A. Fasoli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1518767

4 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1518767

4 October 2022

publication date

1 April 1992

1 reference

8 April 2018

published in

Pharmacological Research

1 reference

8 April 2018

volume

25

1 reference

8 April 2018

issue

3

1 reference

8 April 2018

page(s)

237-245

1 reference

8 April 2018

Lipid disorders in diabetes

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2805%2980072-6

7 January 2021

Non-insulin-dependent diabetes mellitus, abnormal lipoprotein metabolism, and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2805%2980072-6

7 January 2021

Lipids, diabetes, and coronary heart disease: insights from the Framingham Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2805%2980072-6

7 January 2021

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2805%2980072-6

7 January 2021

Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2805%2980072-6

7 January 2021

Disposition pharmacokinetics of bezafibrate in man

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2805%2980072-6

7 January 2021

Mechanisms decreasing glucose oxidation in diabetes and starvation: role of lipid fuels and hormones.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2805%2980072-6

7 January 2021

Hypertriglyceridemia and carbohydrate intolerance: interrelations and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2805%2980072-6

7 January 2021

Dietary fat and menstrual-cycle effects on the erythrocyte ghost insulin receptor in premenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2805%2980072-6

7 January 2021

Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2805%2980072-6

7 January 2021

[Improvement in diabetes control by treatment with bezafibrate]

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2805%2980072-6

7 January 2021

Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2805%2980072-6

7 January 2021

Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2805%2980072-6

7 January 2021

Lipid-lowering effect of bezafibrate in patients with diabetes mellitus and hyperlipidaemia (author's transl)

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2805%2980072-6

7 January 2021

Effects of clofibrate on glucose tolerance, serum insulin, serum lipoproteins and plasma fibrinogen

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2805%2980072-6

7 January 2021

Potentiation of Hypoglycemic Effect of Sulfonylureas by Clofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2805%2980072-6

7 January 2021

Effect of fatty acids on glucose production and utilization in man

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2805%2980072-6

7 January 2021

10.1016/S1043-6618(05)80072-6

Identifiers

DOI

1 reference

8 April 2018

1 reference

8 April 2018